We could not find any results for:
Make sure your spelling is correct or try broadening your search.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated... FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Show more
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYOยฎ in patients with select solid tumorsFibroGen to...
The safety and efficacy of FG-3165 will be evaluated in a Phase 1 trial in select solid tumorsPlan to begin enrollment in 2H 2024 SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen...
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a Fireside Chat at Goldman Sachs...
FG-3246 and enzalutamide combination therapy led to a median radiographic progression free survival (rPFS) of 10.2 months in biomarker unselected patientsFG-3246 demonstrated an acceptable safety...
A California-based biotech company is stealing the show so far during Tuesday’s session after the company reported Q1 2024 earnings after yesterday’s market To read the full story on...
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc.ย (NASDAQ: FGEN) today announced that the companyโs management will participate in the following investor conferences: Bank of...
Topline data from the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer anticipated in mid-2024Topline data from LAPIS Phase 3 study in...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1304 | -9.8045112782 | 1.33 | 1.475 | 1.11 | 2088363 | 1.21285553 | CS |
4 | -0.1104 | -8.42748091603 | 1.31 | 1.74 | 1.0601 | 3532728 | 1.28866566 | CS |
12 | -0.6004 | -33.3555555556 | 1.8 | 2.8 | 0.90105 | 2286249 | 1.48749442 | CS |
26 | 0.5746 | 91.936 | 0.625 | 2.93 | 0.55 | 2435590 | 1.54512808 | CS |
52 | -16.4904 | -93.2187676653 | 17.69 | 19.47 | 0.3333 | 3108049 | 1.96287277 | CS |
156 | -19.9904 | -94.338839075 | 21.19 | 30.1249 | 0.3333 | 1690613 | 7.02775666 | CS |
260 | -36.1604 | -96.7890792291 | 37.36 | 57.2088 | 0.3333 | 1331284 | 14.32810582 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions